Results 181 to 190 of about 673,896 (307)

Remarkable increase in Interleukin-5 receptor expression beyond tissue eosinophils in inflammatory bowel disease. [PDF]

Front Immunol
Kim YI, Oh HJ, Yang HR.
europepmc   +1 more source

Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access. [PDF]

BMJ Open Respir Res, 2022
O'Leary C, Schultz C, Walsh C, Adams R, Casey D, Lane S, Harrison M, Doyle S, Costello RW, King F, Murphy DM.   +10 more
europepmc   +1 more source

Natural Products Inspired Scaffold Diversification Leads to Unnatural Molecular Warhead and Covalent Strategy to Modulating Protein Function through Electrophilic Bromine Transfer

Advanced Science, EarlyView.
We report a new thiolate‐reactive α,α‐gem‐dibromo lactam warhead that activates transcription factor Nrf2 and demonstrates anti‐inflammatory activities, which have implications in cancer, neurodegeneration, and cardiovascular diseases. RNA‐seq illuminated detailed transcriptional profiles, and chemical reactions with cysteine‐containing compounds ...
Beau R. Brummel, Sofia Kokkaliari, Qiwen Gao, Jinjing Chen, Larissa Costa de Almeida, Srinivasarao Tenneti, Derek A. Leas, Eli Levit, Lewis S. Alexander, Khalil A. Abboud, Pingrong Wei, Michael D. Cameron, James R. Rocca, Ranjala Ratnayake, Donna D. Zhang, Hendrik Luesch, Robert W. Huigens III   +16 more
wiley   +1 more source

Anti-interleukin-5 efficacy in an inclisiran-triggered eosinophilic myocarditis: a case report. [PDF]

Eur Heart J Case Rep
Tartaglia F, Messina MR, Rizzo S, Heffler E, Panico C.   +4 more
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Correspondence to 'Interleukin-5 as a Pleiotropic Cytokine Orchestrating Airway Type 2 Inflammation: Effects on and Beyond Eosinophils'. [PDF]

Allergy
McCrae C, Jison ML, Menzies-Gow A.
europepmc   +1 more source

Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α - benralizumab. [PDF]

Cent Eur J Immunol, 2021
Kosałka-Węgiel J, Milewski M, Siwiec A, Strach M, Ochrem B, Korkosz M.   +5 more
europepmc   +1 more source

BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer‐Associated Fibroblasts Crosstalk

Advanced Science, EarlyView.
This study reveals that m6A regulators cooperatively upregulate BGN in melanoma, promoting malignancy. Within the tumor microenvironment, CAFs show highest BGN expression. The BGN/MDK axis mediates cancer‐stroma crosstalk, driving normal fibroblast (NF) activation and enhancing the pro‐tumor effect of CAFs, highlighting a promising therapeutic target ...
Hao‐ze Shi, Ming‐yang Wu, Jin‐quan Liu, Cuicui Tian, Li Ma, Xue‐mei Zhou, Ze‐Hao Sun, Zhi‐yong Xu, Run‐dong Zhang, Shan‐yuan Ye, Li‐ming Huang, Yan Wang, Jing‐shu Xiong, Wen‐bo Bu, Xian‐feng Cheng, Jian‐fang Sun, Hao Chen   +16 more
wiley   +1 more source

Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial. [PDF]

ERJ Open Res
Brinkmann L, Fuge J, Welte T, Suhling H, Drick N.   +4 more
europepmc   +1 more source

Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia. [PDF]

J Asthma Allergy, 2021
Kawabata H, Satoh M, Yatera K.
europepmc   +1 more source